Quick Answer
CytoMed Therapeutics Ltd reported R&D Expense of $2.22 million for fiscal year 2025.
CytoMed Therapeutics Ltd R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.22M | +16.1% |
| 2024 | $1.91M | +20.1% |
| 2023 | $1.59M | +4.4% |
| 2022 | $1.52M | +39.6% |
| 2021 | $1.09M | +5.1% |
| 2020 | $1.04M | — |
- CytoMed Therapeutics Ltd showed an increase of +16.1% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, CytoMed Therapeutics Ltd’s r&d expense has grown by 113.6% (from $1.04 million to $2.22 million).
- The most recent figure is from CytoMed Therapeutics Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: